{"classes":[{"categories":[{"measurements":[{"comment":"No upper limit or median estimate can be provided as the median survival time has not been reached.","groupId":"OG000","lowerLimit":"14.2","upperLimit":"NA","value":"NA"},{"comment":"No upper limit or median estimate can be provided as the median survival time has not been reached.","groupId":"OG001","lowerLimit":"7.6","upperLimit":"NA","value":"16.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"37"}],"units":"Participants"}],"description":"Survival is defined as the duration alive from study entry until death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Everolimus 10 mg daily plus letrozole 2.5 mg PO daily in a 28 day cycle.","id":"OG000","title":"Everolimus and Letrozole"},{"description":"Tamoxifen 20 mg PO bid days 1-28 plus medroxyprogesterone acetate 200 mg PO days 8-14 and 22-28 repeating in a 28 day cycle.","id":"OG001","title":"Tamoxifen and Medroxyprogesterone Acetate"}],"paramType":"MEDIAN","populationDescription":"Eligible patients","reportingStatus":"POSTED","timeFrame":"Following treatment discontinuation, patients are followed quarterly for 2 years, semi-annually for 3 more years, annually thereafter.","title":"Median Survival","type":"SECONDARY","unitOfMeasure":"Months"}